Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Day 2 - The Landscape of Cancer Research: Advances in Immuno-Oncology 2026
About This Webinar
This online symposium will provide a wide-ranging view of immuno-oncology and its role in the future of cancer treatment. Through discussions on current progress and ongoing challenges, attendees will explore how immune-based strategies are reshaping oncology research and patient care.
Featured Presenters
Chief Executive Officer - OncoHost
Beyond Tumor-Centric Precision: Host-Response Biology Redefines Immuno-Oncology Decision Making
07:00 - 08:00 PDT / 10:00 - 11:00 EDT / 15:00 - 16:00 BST
Dr. Ofer Sharon is a physician and entrepreneur with over two decades of experience in clinical research, pharmaceuticals, and biotechnology. Prior to joining OncoHost, Sharon held senior positions in global pharmaceutical companies, including AstraZeneca and MSD (Merck), and was part of the development and clinical launch team for Keytruda. In addition, Sharon has been involved in the establishment of several healthcare companies focused on bioinformatics and machine learning (ML) platforms for clinical deterioration detection and early intervention.
07:00 - 08:00 PDT / 10:00 - 11:00 EDT / 15:00 - 16:00 BST
Dr. Ofer Sharon is a physician and entrepreneur with over two decades of experience in clinical research, pharmaceuticals, and biotechnology. Prior to joining OncoHost, Sharon held senior positions in global pharmaceutical companies, including AstraZeneca and MSD (Merck), and was part of the development and clinical launch team for Keytruda. In addition, Sharon has been involved in the establishment of several healthcare companies focused on bioinformatics and machine learning (ML) platforms for clinical deterioration detection and early intervention.
Senior Fellow, Immunology - Cell Signaling Technology
Novel Monoclonal Antibodies for the Characterization of CAR-Engineered Immune Cells
07:50 - 08:10 PDT / 10:50 - 11:10 EDT / 15:50 - 16:10 BST
Dr. Amrik Singh is a Senior Fellow in Immunology at Cell Signaling Technology (CST), where he leverages over 16 years of industry experience to advance early-stage drug discovery, assay development, and molecular biology workflows. A deeply technical scientist, Dr. Singh has broad expertise across cancer biology and signal transduction pathways—specifically relating to cell growth, proliferation, and apoptosis. Prior to joining CST, Dr. Singh completed his doctoral research at the Boston University School of Medicine, focusing on angiogenic signal relay via VEGFR-2 , followed by a postdoctoral research fellowship at BIDMC/Harvard Medical School studying the molecular mechanisms of oncogenic protein kinases and transcription factors. At CST, he works at the intersection of high-quality antibody development and advanced translational applications to provide researchers with robust, highly reproducible quantitative tools with a focus on developing antibodies and assays to enable cell therapy research.
07:50 - 08:10 PDT / 10:50 - 11:10 EDT / 15:50 - 16:10 BST
Dr. Amrik Singh is a Senior Fellow in Immunology at Cell Signaling Technology (CST), where he leverages over 16 years of industry experience to advance early-stage drug discovery, assay development, and molecular biology workflows. A deeply technical scientist, Dr. Singh has broad expertise across cancer biology and signal transduction pathways—specifically relating to cell growth, proliferation, and apoptosis. Prior to joining CST, Dr. Singh completed his doctoral research at the Boston University School of Medicine, focusing on angiogenic signal relay via VEGFR-2 , followed by a postdoctoral research fellowship at BIDMC/Harvard Medical School studying the molecular mechanisms of oncogenic protein kinases and transcription factors. At CST, he works at the intersection of high-quality antibody development and advanced translational applications to provide researchers with robust, highly reproducible quantitative tools with a focus on developing antibodies and assays to enable cell therapy research.
Chief Operations Officer - ViroMissile
Microphysiological Engineering of 3D Vascularized Human Tissues to Study Complex Diseases
08:10 - 09:00 PDT / 11:10 - 12:00 EDT / 16:10 - 17:00 BST
Mark Bertagnolli is the Chief Operating Officer of ViroMissile and serves on its board of directors, having served previously as the Company’s Chief Business Officer. Before ViroMissile, Mark was founder of Amitech Therapeutic Solutions, a small molecule biotechnology company, after serving as Genelux Corporation’s Chief Business Officer, where he worked with ViroMissile’s founder, Dr. Nanhai George Chen.
Mark earned a Bachelor of Science in Aerospace Engineering, cum laude, from the University of Michigan, Ann Arbor, and is a Certified Director by NACD.
08:10 - 09:00 PDT / 11:10 - 12:00 EDT / 16:10 - 17:00 BST
Mark Bertagnolli is the Chief Operating Officer of ViroMissile and serves on its board of directors, having served previously as the Company’s Chief Business Officer. Before ViroMissile, Mark was founder of Amitech Therapeutic Solutions, a small molecule biotechnology company, after serving as Genelux Corporation’s Chief Business Officer, where he worked with ViroMissile’s founder, Dr. Nanhai George Chen.
Mark earned a Bachelor of Science in Aerospace Engineering, cum laude, from the University of Michigan, Ann Arbor, and is a Certified Director by NACD.
Technical Sales Manager, ACROBiosystems
Leveraging AI and Research Platforms to Accelerate Next-gerneration Biological Modalities
09:00 - 09:20 PDT / 12:00- 12:20 EDT / 17:00 - 17:20 BST
Cody White is a Technical Sales Manager at ACROBiosystems, supporting biopharma and biotechnology companies across North America developing advanced therapeutics. He works with scientists and CMC teams to solve challenges from early discovery through GMP manufacturing, with expertise in cell and gene therapies, mRNA therapeutics and vaccines, recombinant and monoclonal antibodies, and ADCs. His focus includes assay development, cell line engineering, residuals testing, and regulatory readiness, helping customers implement robust, quality-driven workflows. He also supports sales enablement and strategic account planning, translating complex scientific requirements into scalable solutions that accelerate the development of next-generation biologics, cell therapies, and gene therapies.
09:00 - 09:20 PDT / 12:00- 12:20 EDT / 17:00 - 17:20 BST
Cody White is a Technical Sales Manager at ACROBiosystems, supporting biopharma and biotechnology companies across North America developing advanced therapeutics. He works with scientists and CMC teams to solve challenges from early discovery through GMP manufacturing, with expertise in cell and gene therapies, mRNA therapeutics and vaccines, recombinant and monoclonal antibodies, and ADCs. His focus includes assay development, cell line engineering, residuals testing, and regulatory readiness, helping customers implement robust, quality-driven workflows. He also supports sales enablement and strategic account planning, translating complex scientific requirements into scalable solutions that accelerate the development of next-generation biologics, cell therapies, and gene therapies.
Hematology Oncology - Meyer Cancer Center of New York-Presbyterian Hospital
The Future of Lymphoma Care: AI, Decision-Making and the Next Clinical Paradigm
09:20 - 10:10 PDT / 12:20 - 13:10 EDT / 17:20 - 18:10 BST
Dr. Yan Leyfman is a rising star in oncology and AI, recently recognized as a 40 Under 40 Emerging Leader in Cancer at the 2023 ASCO Annual Meeting. During the COVID-19 pandemic, he led the Immunology Division of the Global COVID-19 Taskforce, pioneering the first mechanisms for SARS-CoV-2 and COVI-Flu. His groundbreaking research on the cancer-COVID-19 interplay, presented at ASCO 2021 and published in BMC Journal of Hematology & Oncology, has significant clinical implications, earning him recognition as a 2022 International Hero in Healthcare by the Lymphoma, Leukemia & Myeloma Congress. Dr. Leyfman has made key contributions to advancing CAR T cell therapies, currently in clinical trials, earning honors such as the 2020 iCHEM Emerging International Scholar Award and the 2023 Young Scientists Phacilitate Advanced Therapies Award.
09:20 - 10:10 PDT / 12:20 - 13:10 EDT / 17:20 - 18:10 BST
Dr. Yan Leyfman is a rising star in oncology and AI, recently recognized as a 40 Under 40 Emerging Leader in Cancer at the 2023 ASCO Annual Meeting. During the COVID-19 pandemic, he led the Immunology Division of the Global COVID-19 Taskforce, pioneering the first mechanisms for SARS-CoV-2 and COVI-Flu. His groundbreaking research on the cancer-COVID-19 interplay, presented at ASCO 2021 and published in BMC Journal of Hematology & Oncology, has significant clinical implications, earning him recognition as a 2022 International Hero in Healthcare by the Lymphoma, Leukemia & Myeloma Congress. Dr. Leyfman has made key contributions to advancing CAR T cell therapies, currently in clinical trials, earning honors such as the 2020 iCHEM Emerging International Scholar Award and the 2023 Young Scientists Phacilitate Advanced Therapies Award.
President & Chief Scientific Officer - Kairos Pharma
Overcoming Barriers in Cancer Drug Resistance
10:10 - 11:00 PDT / 13:10 - 14:00 EDT / 18:10 - 19:00 BST
A leading cancer biologist and translational researcher, Dr. Bhowmick is the Mark Goodson Oncology Research Chair and Professor in the Department of Medicine at Cedars-Sinai Medical Center. He also serves as the Chief Scientific Officer for Armida Labs as well as President of Enviro Therapeutics Inc. He completed a research fellowship at Vanderbilt University Medical Center. Dr. Bhowmick’s research has been continuously funded by the NCI/NIH for more than 20 years in the field of tumor microenvironment involving basic and clinical research for multiple cancer types.
10:10 - 11:00 PDT / 13:10 - 14:00 EDT / 18:10 - 19:00 BST
A leading cancer biologist and translational researcher, Dr. Bhowmick is the Mark Goodson Oncology Research Chair and Professor in the Department of Medicine at Cedars-Sinai Medical Center. He also serves as the Chief Scientific Officer for Armida Labs as well as President of Enviro Therapeutics Inc. He completed a research fellowship at Vanderbilt University Medical Center. Dr. Bhowmick’s research has been continuously funded by the NCI/NIH for more than 20 years in the field of tumor microenvironment involving basic and clinical research for multiple cancer types.
Recommended